Anovulatory, Polycystic Ovary Syndrome
Conditions
Brief summary
The participants will receive metformin 500mg 3times per day for 3months and one month is left for spontaneous pregnancy to occur or not (primary outcome ) and the investigators will check endometrial thickness and subendometerial vascularity as markers of endometrial receptivity before and after the treatment.
Interventions
DRUGMetformin
Metformin to increase pregnancy rate in polycystic ovarian syndrome patients
Sponsors
Ain Shams Maternity Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
* PCO syndrome patients have the following criteria: Age of the patient between 20 - 40 years old. All subjects are not on a specific diet nor a certain program of physical exercise Complaining of infertility either primary or secondary due to PCOS. N.B: The diagnosis of PCO syndrome was made according to the Androgen Excess and Polycystic Ovarian Syndrome Society: the presence of the following criteria have been required for the diagnosis of PCO syndrome: Hyperandrogenism: Hirsutism and/or Hyperandrogenaemia Ovarian Dysfunction : Oligo-Anovulation and /or Polycystic ovaries Exclusion of other Androgen Excess or related disorders as :( deficient nonclassic adrenal hyperplasia, androgen-secreting neoplasms, androgenic/anabolic drug use or abuse, Cushing's syndrome, the Hyperandrogenic-Insulin Resistance-Acanthosis Nigricans syndrome, thyroid dysfunction, and hyperprolactinemia).
Exclusion criteria
* Age below 20 or above 40. Women who intended to start a diet or a specific program of physical activity. Concurrent medical illness as cardiovascular, neoplastic and hepatic disorder. Pelvic pathology. Tubal, Uterine, Male factor of infertility. Endocrinological factors including: diabetes Mellitus,hypothyroidism, hyperprolactinaemia, Cushing's syndrome, and non- classical congenital adrenal hyperplasia. Patients who are ovulatory during the ovarian cycle
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| pregnancy | 4 months | polycystic ovarian syndrome patients getting pregnant on receiving Metformin |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Endometrial thickness and Sub Endometrial vascularity | 4 months | Endometrial thickness and Sub Endometrial vascularity before and after receiving Metformin as markers of endometrial receptivity |
Countries
Egypt
Outcome results
None listed